Table of Contents Author Guidelines Submit a Manuscript
Erratum

An erratum for this article has been published. To view the erratum, please click here.

PPAR Research
Volume 2014, Article ID 215631, 10 pages
http://dx.doi.org/10.1155/2014/215631
Research Article

15-Deoxy-γ12,14-prostaglandin J2 Reduces Liver Impairment in a Model of ConA-Induced Acute Hepatic Inflammation by Activation of PPARγ and Reduction in NF-κB Activity

1Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
2Tongji University School of Medicine, Shanghai 200092, China

Received 29 April 2014; Revised 22 June 2014; Accepted 23 June 2014; Published 10 July 2014

Academic Editor: Paul D. Drew

Copyright © 2014 Kan Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. F. Eggink, H. J. Houthoff, S. Huitema, C. H. Gips, and S. Poppema, “Cellular and humoral immune reactions in chronic active liver disease. I. Lymphocyte subsets in liver biopsies of patients with untreated idiopathic autoimmune hepatitis, chronic active hepatitis B and primary biliary cirrhosis,” Clinical & Experimental Immunology, vol. 50, pp. 17–24, 1982. View at Google Scholar
  2. H. Mizuhara, E. O'Neill, N. Seki et al., “T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6,” The Journal of Experimental Medicine, vol. 179, pp. 1529–1537, 1994. View at Google Scholar
  3. M. Nakaya, M. Hashimoto, R. Nakagawa et al., “SOCS3 in T and NKT cells negatively regulates cytokine production and ameliorates ConA-induced hepatitis,” The Journal of Immunology, vol. 183, no. 11, pp. 7047–7053, 2009. View at Publisher · View at Google Scholar
  4. G. Tiegs, J. Hentschel, and A. Wendel, “A T cell-dependent experimental liver injury in mice inducible by concanavalin A,” Journal of Clinical Investigation, vol. 90, pp. 196–203, 1992. View at Publisher · View at Google Scholar
  5. X. Zhang, H. X. Wei, S. Rui, H. Wei, and Z. Tian, “Opposite effects of high and low doses of interleukin-2 on T cell-mediated hepatitis in mice (interleukin-2 on hepatitis),” Hepatology International, vol. 4, no. 3, pp. 641–648, 2010. View at Publisher · View at Google Scholar
  6. F. A. Fitzpatrick and M. A. Wynalda, “Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro,” The Journal of Biological Chemistry, vol. 258, pp. 11713–11718, 1983. View at Google Scholar
  7. C. D. Funk, “Prostaglandins and leukotrienes: advances in eicosanoid biology,” Science, vol. 294, pp. 1871–1875, 2001. View at Publisher · View at Google Scholar
  8. T. Shibata, M. Kondo, T. Osawa, N. Shibata, M. Kobayashi, and K. Uchida, “15-deoxy-delta 12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes,” The Journal of Biological Chemistry, vol. 277, no. 12, pp. 10459–10466, 2002. View at Publisher · View at Google Scholar
  9. D. W. Gilroy, P. R. Colville-Nash, D. Willis et al., “Inducible cyclooxygenase may have anti-inflammatory properties,” Nature Medicine, vol. 5, no. 6, pp. 698–701, 1999. View at Google Scholar
  10. Y. Yoshikai, “Roles of prostaglandins and leukotrienes in acute inflammation caused by bacterial infection,” Current Opinion in Infectious Diseases, vol. 14, no. 3, pp. 257–263, 2001. View at Publisher · View at Google Scholar
  11. X. Liu, H. Yu, L. Yang, C. Li, and L. Li, “15-Deoxy-Delta(12, 14)-prostaglandin J(2) attenuates the biological activities of monocyte/macrophage cell lines,” European Journal of Cell Biology, vol. 91, pp. 654–661, 2012. View at Publisher · View at Google Scholar
  12. C. Jiang, A. T. Ting, and B. Seed, “PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Google Scholar
  13. Z. Han, T. Zhu, X. Liu et al., “15-deoxy-Δ12,14-prostaglandin J2 reduces recruitment of bone marrow-derived monocyte/macrophages in chronic liver injury in mice,” Hepatology, vol. 56, no. 1, pp. 350–360, 2012. View at Publisher · View at Google Scholar
  14. C. Alves, N. de Melo, L. Fraceto, D. de Araujo, and M. Napimoga, “Effects of 15d-PGJ(2)-loaded poly(D,L-lactide-co-glycolide) nanocapsules on inflammation,” British Journal of Pharmacology, vol. 162, no. 3, pp. 623–632, 2011. View at Google Scholar
  15. B. Zingarelli, M. Sheehan, P. W. Hake, M. O'Connor, A. Denenberg, and J. A. Cook, “Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways,” The Journal of Immunology, vol. 171, no. 12, pp. 6827–6837, 2003. View at Publisher · View at Google Scholar
  16. L. Dugo, M. Collin, S. Cuzzocrea, and C. Thiemermann, “15d-prostaglandin J2 reduces multiple organ failure caused by wall-fragment of Gram-positive and Gram-negative bacteria,” European Journal of Pharmacology, vol. 498, pp. 295–301, 2004. View at Google Scholar
  17. A. Cloutier, I. Marois, D. Cloutier et al., “The prostanoid 15-deoxy-Delta12, 14-prostaglandin-j2 reduces lung inflammation and protects mice against lethal influenza infection,” The Journal of Infectious Diseases, vol. 205, pp. 621–630, 2012. View at Google Scholar
  18. A. Rossi, P. Kapahi, G. Natoli et al., “Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase,” Nature, vol. 403, no. 6765, pp. 103–108, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Shiraki, N. Kamiya, S. Shiki et al., “Alpha, beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gamma,” The Journal of Biological Chemistry, vol. 280, pp. 14145–14153, 2005. View at Google Scholar
  20. Y. Ogawa, M. Yoneda, W. Tomeno, K. Imajo, and Y. Shinohara, “Peroxisome proliferator-activated receptor gamma exacerbates concanavalin a-induced liver injury via suppressing the translocation of NF-κB into the nucleus,” PPAR Research, vol. 2012, Article ID 940384, 5 pages, 2012. View at Publisher · View at Google Scholar
  21. C. C. Li, H. T. Yang, Y. C. Hou, Y. S. Chiu, and W. C. Chiu, “Dietary fish oil reduces systemic inflammation and ameliorates sepsis-induced liver injury by up-regulating the peroxisome proliferator-activated receptor gamma-mediated pathway in septic mice,” Journal of Nutritional Biochemistry, vol. 25, pp. 19–25, 2014. View at Publisher · View at Google Scholar
  22. M. Ricote, J. Huang, L. Fajas et al., “Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, pp. 7614–7619, 1998. View at Google Scholar
  23. T. Sasaguri and Y. Miwa, “Prostaglandin J2 family and the cardiovascular system,” Current Vascular Pharmacology, vol. 2, no. 2, pp. 103–114, 2004. View at Publisher · View at Google Scholar
  24. K. Hashimoto, R. T. Ethridge, H. Saito, S. Rajaraman, and B. M. Evers, “The PPARgamma ligand, 15d-PGJ2, attenuates the severity of cerulein-induced acute pancreatitis,” Pancreas, vol. 27, no. 1, pp. 58–66, 2003. View at Google Scholar
  25. N. Baregamian, J. M. Mourot, A. R. Ballard, B. M. Evers, and D. H. Chung, “PPAR-γ agonist protects against intestinal injury during necrotizing enterocolitis,” Biochemical and Biophysical Research Communications, vol. 379, no. 2, pp. 423–427, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Xu, J. Li, W. Ni, Y. W. Shen, and X. P. Zhang, “Peroxisome proliferator-activated receptor-γ agonist 15d-prostaglandin J2 mediates neuronal autophagy after cerebral ischemia-reperfusion injury,” PLoS ONE, vol. 8, no. 1, Article ID e55080, 2013. View at Publisher · View at Google Scholar
  27. M. M. Buckner, L. C. Antunes, N. Gill, S. L. Russell, and S. R. Shames, “15-deoxy-Δ12,14-prostaglandin J2 inhibits macrophage colonization by Salmonella enterica serovar Typhimurium,” PLoS ONE, vol. 8, Article ID e69759, 2013. View at Publisher · View at Google Scholar
  28. Y. Nozaki, K. Harada, T. Sanzen, and Y. Nakanuma, “PPARγ ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis,” Medical Molecular Morphology, vol. 46, no. 3, pp. 153–159, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Boyault, M. A. Simonin, A. Bianchi, E. Compe, and B. Liagre, “15-Deoxy-Δ12 ,14-PGJ2, but not troglitazone , modulates IL-1β effects in human chondrocytes by inhibiting NF-κB and AP-1 activation pathways,” FEBS Letters, vol. 501, pp. 24–30, 2001. View at Publisher · View at Google Scholar
  30. S. Giri, R. Rattan, A. K. Singh, and I. Singh, “The 15-deoxy-delta12, 14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma,” The Journal of Immunology, vol. 173, pp. 5196–5208, 2004. View at Publisher · View at Google Scholar
  31. H. P. Raikwar, G. Muthian, J. Rajasingh, C. N. Johnson, and J. J. Bright, “PPARgamma antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-deoxy-Delta12,14-prostaglandin J2,” Journal of Neuroimmunology, vol. 178, no. 1-2, pp. 76–86, 2006. View at Google Scholar
  32. C. Natarajan and J. J. Bright, “Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation,” Genes and Immunity, vol. 3, no. 2, pp. 59–70, 2002. View at Publisher · View at Google Scholar
  33. K. Uchida and T. Shibata, “15-Deoxy-Δ12,14-prostaglandin J2: an electrophilic trigger of cellular responses,” Chemical Research in Toxicology, vol. 21, no. 1, pp. 138–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. W. K. Jung, I. S. Park, S. J. Park et al., “The 15-deoxy-Delta12,14-prostaglandin J2 inhibits LPS-stimulated AKT and NF- kappaB activation and suppresses interleukin-6 in osteoblast-like cells MC3T3E-1,” Life Sciences, vol. 85, pp. 46–53, 2009. View at Publisher · View at Google Scholar
  35. W. T. Ackerman, X. L. Zhang, B. H. Rovin, and D. A. Kniss, “Modulation of cytokine-induced cyclooxygenase 2 expression by PPARG ligands through NFkappaB signal disruption in human WISH and amnion cells,” Biology of Reproduction, vol. 73, pp. 527–535, 2005. View at Publisher · View at Google Scholar
  36. A. Ciucci, P. Gianferretti, R. Piva et al., “Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway,” Molecular Pharmacology, vol. 70, no. 5, pp. 1812–1821, 2006. View at Google Scholar
  37. R. Kostadinova, W. Wahli, and L. Michalik, “PPARs in diseases: Control mechanisms of inflammation,” Current Medicinal Chemistry, vol. 12, no. 25, pp. 2995–3009, 2005. View at Publisher · View at Google Scholar · View at Scopus